Date : Since 03/06/2020
Place : Montigny le BretonneuxBioreagents
Angiotensin II – a peptide hormone that increases blood pressure- has recently been involved in several studies regarding the Covid-19 pandemic. Indeed, SARS-CoV-2 gains entry to lung cells after binding to ACE2, an enzyme which converts Angiotensin II to Angiotensin 1-7.
A large body of literature discusses the hypothesis that Angiotensin receptor-blocking drugs (ARBs) might be responsible for the increased severity of Covid-19 symptoms in hypertensive patients. (1,2) Hypertension by itself does not impact any other types of infections, but some of the most commonly used hypertensive drugs, ARBs, are very likely to promote ACE2 expression (3,4), potentially by increasing plasma levels of Angiotensin II (5,6). This would in turn facilitate SARS-CoV-2 entry into the pulmonary cells.
On a more fundamental level, some researchers have identified Angiotensin II as a potential cause for some of the symptoms of Covid-19. SARS-CoV-2 binding to ACE2 might lead to reducing the activity of this enzyme (7). Decreased ACE2 activity would result in an imbalance between Angiotensin II and Angiotensin 1-7, in favor of a higher level of Angiotensin II. High circulating levels of Ang II are known to cause pulmonary vasoconstriction, which induces ventilation–perfusion mismatch and promotes vascular permeability, inflammation, and oxidative stress and can result in acute lung injury or acute respiratory distress syndrome (ARDS). (8)
Bertin Bioreagent offers a comprehensive range of reagents to study Angiotensin II. The Angiotensin II ELISA kit, will allow you to quantify Angiotensin II levels in plasma as well as culture supernatants in all mammalian species, with a high sensitivity (detection limit: 1pg/mL), while the Angiotensin II inhibition cocktail will protect angiotensin II of your samples from degradation.
 : ESLER, Murray et ESLER, Danielle. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?. Journal of hypertension, 2020, vol. 38, no 5, p. 781-782.
: ZHANG, Peng, ZHU, LiHua, CAI, Jingjing, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation research, 2020.
: Jessup JA, Gallagher PE, Averill DB, Brosnihan B, Tallant A, Chappell MC, et al. Effect of angiotension blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ 2006; 291:H2166–H2172.
: Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605–2610.
: Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88 (4 Pt 1):1602–1609.
: Bauer IH, Reams GP, Wu Z, Lau-Sieckman A. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995; 9:237–243.
 ZAVASCKI, Alexandre P. et FALCI, Diego R. Clinical characteristics of COVID-19 in china. World, 2020, vol. 727, p. 33.
 Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care 2017; 21: 305.